Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs Pertuzumab (Primary) ; Docetaxel; Trastuzumab
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEOPATRA
  • Sponsors Chugai Pharmaceutical; Genentech; Roche
  • Most Recent Events

    • 14 Dec 2018 Status changed from active, no longer recruiting to completed.
    • 16 Oct 2018 Planned End Date changed from 23 Oct 2018 to 14 Nov 2018.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top